$102 Million is the total value of Burrage Capital Management LLC's 31 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 35.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EPZM | Sell | EPIZYME INC | $12,539,000 | -47.2% | 893,698 | -7.4% | 12.34% | -22.5% |
| PTCT | Sell | PTC THERAPEUTICS INC | $8,156,000 | -13.2% | 181,237 | -7.4% | 8.03% | +27.4% |
| KIDS | Sell | ORTHOPEDIATRICS CORP | $6,673,000 | -23.5% | 171,113 | -7.8% | 6.57% | +12.4% |
| NEO | Sell | NEOGENOMICS INC | $5,238,000 | -9.7% | 192,277 | -3.1% | 5.16% | +32.6% |
| ISEE | Sell | IVERIC BIO INC | $4,990,000 | -64.8% | 1,521,382 | -7.9% | 4.91% | -48.3% |
| ANAB | Sell | ANAPTYSBIO INC COM | $4,481,000 | -23.4% | 331,919 | -7.8% | 4.41% | +12.4% |
| MEIP | Sell | MEI PHARMA INC | $4,467,000 | -42.4% | 3,018,059 | -3.4% | 4.40% | -15.4% |
| YMAB | Sell | Y-MABS THERAPEUTICS INC | $4,413,000 | -24.4% | 171,788 | -8.0% | 4.34% | +11.0% |
| GTHX | Sell | G1 THERAPEUTICS INC | $3,895,000 | -64.4% | 378,145 | -8.8% | 3.83% | -47.8% |
| CARA | Sell | CARA THERAPEUTICS INC | $3,292,000 | -28.1% | 258,766 | -8.9% | 3.24% | +5.6% |
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $2,038,000 | -11.5% | 74,452 | -1.0% | 2.01% | +30.0% |
| AERI | Sell | AERIE PHARMACEUTICALS INC | $1,185,000 | -73.9% | 88,445 | -52.9% | 1.17% | -61.7% |
| WVE | Sell | WAVE LIFE SCIENCES LTD | $556,000 | -34.5% | 56,699 | -46.5% | 0.55% | -3.9% |
| SLDB | Exit | Solid Biosciences Inc | $0 | – | -80,487 | -100.0% | -0.24% | – |
| ABMD | Exit | ABIOMED Inc | $0 | – | -10,138 | -100.0% | -1.16% | – |
| DRNA | Exit | Dicerna Pharmaceuticals Inc | $0 | – | -104,047 | -100.0% | -1.54% | – |
| USPH | Exit | US Physical Therapy Inc | $0 | – | -21,500 | -100.0% | -1.65% | – |
| DCPH | Exit | Deciphera Pharmaceuticals Inc | $0 | – | -59,818 | -100.0% | -2.50% | – |
| ASND | Exit | Ascendis Pharma A/Ssponsored adr | $0 | – | -43,775 | -100.0% | -4.08% | – |
| ARQL | Exit | ArQule Inc | $0 | – | -595,018 | -100.0% | -7.96% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| EPIZYME INC COM | 7 | Q2 2021 | 15.9% |
| NeoGenomics Inc | 7 | Q2 2021 | 8.7% |
| OrthoPediatrics Corp | 7 | Q2 2021 | 7.3% |
| Y-MABS THERAPEUTICS INC COM | 7 | Q2 2021 | 4.3% |
| CRINETICS PHARMACEUTICALS INC COM | 7 | Q2 2021 | 5.6% |
| G1 THERAPEUTICS INC COM | 7 | Q2 2021 | 7.3% |
| PTC THERAPEUTICS INC COM | 6 | Q1 2021 | 8.0% |
| CYTOKINETICS INC COM NEW | 6 | Q2 2021 | 4.9% |
| TURNING PT THERAPEUTICS INC COM | 6 | Q2 2021 | 6.7% |
| APELLIS PHARMACEUTICALS INC COM | 6 | Q1 2021 | 3.5% |
View Burrage Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Protalix BioTherapeutics, Inc.Sold out | July 30, 2021 | 0 | 0.0% |
| IVERIC bio, Inc. | February 14, 2020 | 10 | 3.4% |
View Burrage Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| SC 13G/A | 2021-07-30 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-12 |
| SC 13G | 2021-02-12 |
| 13F-HR | 2020-11-13 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-14 |
| 13F-HR | 2020-02-14 |
View Burrage Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.